Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

Part of paid clinical trials in Tampa, Florida.

Sponsor
Esperion Therapeutics, Inc.
Study ID
NCT03067441
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bempedoic acid — DRUG
    bempedoic acid 180 mg tablets taken orally, once per day.

Study Details

The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.

Key Dates

Start date
Feb 3, 2017
Status verified
Feb 2021
Primary completion
Nov 5, 2019
Completion
Nov 5, 2019

Study Design

Enrollment
1,462 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Open-Label bempedoic acid
    bempedoic acid 180 mg tablet

Primary Outcome Measure

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Up to Week 82 ]

Locations (3)

FacilityCityStateZIPSite coordinators
Jedidiah Clinical ResearchTampaFlorida33607-
L-MARC Research CenterLouisvilleKentucky40213-
Sentral Clinical Research ServicesCincinnatiOhio45236-

Find similar trials in Tampa, FL

By research site
Jedidiah Clinical Research· Tampa, FLL-MARC Research Center· Louisville, KYSentral Clinical Research Services· Cincinnati, OH

Related Studies